Loading...

APC anti-human CD274 (B7-H1, PD-L1) Antibody

Pricing & Availability
Clone
29E.2A3 (See other available formats)
Regulatory Status
RUO
Other Names
Programmed cell death ligand 1 (PD-L1), B7 homolog 1 (B7-H1)
Isotype
Mouse IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
29E.2A3_APC_CD274_Antibody_FC_091013
PHA-stimulated (3 days) human peripheral blood lymphocytes were stained with CD274 (B7-H1, PD-L1) (clone 29E.2A3) APC (filled histogram) or mouse IgG2b, κ APC isotype control (open histogram).
  • 29E.2A3_APC_CD274_Antibody_FC_091013
    PHA-stimulated (3 days) human peripheral blood lymphocytes were stained with CD274 (B7-H1, PD-L1) (clone 29E.2A3) APC (filled histogram) or mouse IgG2b, κ APC isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
329707 25 tests 111€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
329708 100 tests 234€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
African Green, Baboon, Cynomolgus, Rhesus
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Full length human PD-L1
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 29E.2A3 is reported to recognize an epitope on PD-L1 within the PD-L1-CD80 binding region5. Additional reported applications (for the relevant formats) include: blocking1-3 and immunohistochemical staining of acetone-fixed frozen sections1. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329715, 329716, 329745 - 329748). 

It has been observed that clone 29E.2A3 is able to bind to Alexa Fluor® 700 antibody conjugates during multi-color immunofluorescent staining. This interaction can be resolved by sequentially staining with the 29E.2A3 antibody first and then followed by the Alexa Fluor® 700 conjugate of interest.

Clone 29E.2A3 does not work in Western blot applications7.

Application References
  1. Brown J, et al. 2003. J. Immunol. 170:1257. (FC, IHC, Block)
  2. Radziewicz H, et al. 2007. J. Virol. 81:2545. (Block)
  3. Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (Block)
  4. Barsoum IB, et al. 2014. Cancer Res. 74:665. PubMed
  5. Haile, S et al. 2013. J. Immunol. 191:2829.
  6. RL M, et al. 2015. PNAS. 112:6506-6514. PubMed
  7. Mahoney KM, et al. 2015. Cancer Immunol. Res. 3:1308.
Product Citations
  1. Kuryk L, et al. 2019. Oncoimmunology. 8:e1532763. PubMed
  2. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
  3. Chan LC, et al. 2019. J Clin Invest. 129:3324. PubMed
  4. Oreskovic E, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed
  5. Thiramanas R, et al. 2020. Cells. 9: . PubMed
  6. Miliotis C, et al. 2021. Cancer Lett. 518:115. PubMed
  7. Zhang Z, et al. 2022. Cancer Gene Ther. 29:722. PubMed
  8. Kwee BJ, et al. 2021. Proc Natl Acad Sci U S A. 118: . PubMed
  9. Wang W, et al. 2022. Mol Cancer Res. 20:1137. PubMed
  10. Yang Z, et al. 2022. Cancer Discov. 12:1942. PubMed
  11. Liu C, et al. 2022. Cancer Commun (Lond). 42:828. PubMed
  12. Wang Q, et al. 2022. Sci Adv. 8:eabq4722. PubMed
  13. Guo Y, et al. 2023. Mol Carcinog. 62:185. PubMed
  14. De León Rodríguez SG, et al. 2022. J Oncol. 2022:9775736. PubMed
  15. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  16. Wang M, et al. 2022. J Cell Biol. 221:. PubMed
  17. Pan R, et al. 2022. Cell. 185:1521. PubMed
  18. Wang J, et al. 2023. ACS Sens. 8:1200. PubMed
  19. Pinto C, et al. 2023. iScience. 26:106381. PubMed
  20. Lin Z, et al. 2023. J Transl Med. 21:249. PubMed
  21. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  22. Sapski S, et al. 2020. Cancer Immunol Immunother. 2291:69. PubMed
  23. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  24. Rauch DA, et al. 2019. Blood. 134:1406. PubMed
  25. Sun X, et al. 2020. Am J Cancer Res. 10:564. PubMed
  26. Fu Y, et al. 2020. Sci Rep. 10:9027. PubMed
  27. Wang M, et al. 2022. Immun Inflamm Dis. 10:e626. PubMed
  28. Tanaka C, et al. 2021. Molecules. 26:. PubMed
  29. Hakroush S, et al. 2021. Front Immunol. 11:624547. PubMed
  30. Cen B, et al. 2021. Oncogene. 40:5984. PubMed
  31. Leite NC, et al. 2020. Cell Reports. 32(2):107894.. PubMed
  32. Cui J, et al. 2020. Cancers (Basel). 0.596527778. PubMed
  33. Hsu JM, et al. 2018. Nat Commun. 9:1908. PubMed
  34. Jiang X, et al. 2013. Clin Cancer Res. 19:598. PubMed
  35. Ng W, et al. 2021. Pharm Biol. 59:47:00. PubMed
  36. Chou CW, et al. 2020. Am J Cancer Res. 2621:10. PubMed
  37. Li C, et al. 2021. J Immunother Cancer. 9:. PubMed
  38. Shevyrev D, et al. 2021. Exp Ther Med. 209:21. PubMed
  39. Toews K, et al. 2020. Mol Carcinog. 724:59. PubMed
  40. Hsu H, et al. 2016. J Immunol. 197: 1884 - 1892. PubMed
  41. Bernareggi D, et al. 2022. Nat Commun. 13:1899. PubMed
  42. Baleeiro RB, et al. 2022. Oncoimmunology. 11:2080329. PubMed
  43. Chen LM, et al. 2021. Biosci Rep. 41:. PubMed
  44. Boyerinas B, et al. 2015. Cancer Immunol Res. 3: 1148 - 1157. PubMed
  45. Johnson D, et al. 2016. Nat Commun. 7:10582. PubMed
  46. Izmirly AM, et al. 2022. PLoS Pathog. 18:e1009903. PubMed
  47. Taniguchi H, et al. 2022. Cell Rep. 39:110814. PubMed
  48. Xi X, et al. 2021. Oncol Lett. 22:716. PubMed
  49. Kotetsu Y, et al. 2021. Biomedicines. 9:. PubMed
  50. Miranda A, et al. 2015. Cancer Res . 75: 3032-3042. PubMed
  51. Wallstabe L et al. 2019. JCI Insight. 4(18) pii: 126345. PubMed
  52. Su S et al. 2018. Cell. 175(2):442-457 . PubMed
  53. Atefi M, et al. 2014. Clin Cancer Res. 20:3446. PubMed
  54. Arlt A, et al. 2020. Mol Oncol. 14:571. PubMed
  55. Yang WH, et al. 2018. Cancer Res. 78:3761. PubMed
  56. Huang BR, et al. 2020. Int J Mol Sci. 21:00. PubMed
  57. Chen LM, et al. 2021. Biosci Rep. Online ahead of print. PubMed
  58. Fu H, et al. 2021. Front Cell Dev Biol. 9:764109. PubMed
  59. Yoshida R, et al. 2022. Cancer Res. :. PubMed
  60. Koopmans I, et al. 2018. Oncoimmunology. 7:e1466016. PubMed
  61. Lim KH, et al. 2020. Nat Commun. 2.889583333. PubMed
  62. Capuano C, et al. 2018. Front Immunol. 9:1031. PubMed
  63. Zhao L, et al. 2018. Oncol Lett. 16:1180. PubMed
  64. Jiao S, et al. 2017. Clin Cancer Res. 23:3711. PubMed
  65. Palakurthi S, et al. 2019. Cancer Immunol Res. 1.303472222. PubMed
  66. Saraiva DP, et al. 2018. Front Immunol. 2.184027778. PubMed
  67. Wertel I, et al. 2020. J Immunol Res. 1715064:2020. PubMed
  68. Volpin V, et al. 2020. Cancer Immunol Res. 8:1163. PubMed
  69. Li Z, et al. 2020. Front Cell Dev Biol. 8:572689. PubMed
  70. Lin G, et al. 2021. Mol Med Rep. 23:. PubMed
  71. Ofori S, et al. 2019. ACS Omega. 4:12584. PubMed
  72. Jin MH, et al. 2019. Cancer Res Treat. N/A. PubMed
  73. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  74. Sam J, et al. 2020. Front Oncol. 10:575737. PubMed
  75. Jiang L, et al. 2019. Sci Rep. 9:3705. PubMed
  76. Wang B, et al. 2018. Mol Ther Nucleic Acids. 0.548611111. PubMed
  77. Gorris MAJ, et al. 2018. J Immunol. 200:347. PubMed
  78. Mackroth M, et al. 2016. PLoS Pathog. 12:e1005909. PubMed
  79. Wang X, et al. 2022. J Exp Clin Cancer Res. 41:210. PubMed
  80. Tameishi M, et al. 2021. Pharmaceuticals (Basel). 14:. PubMed
  81. Liu YS, et al. 2021. Cancers (Basel). 13:. PubMed
  82. O'Connor MH, et al. 2021. Commun Biol. 4:563. PubMed
  83. Luna-Yolba R, et al. 2021. Cancers (Basel). 13: . PubMed
  84. Zheng Y, et al. 2022. Transl Res. :. PubMed
  85. Hassounah NB, et al. 2019. Cancer Immunol Immunother. 68:407. PubMed
  86. Parent AV, et al. 2021. Cell Reports. 36(7):109538. PubMed
  87. An L, et al. 2016. Sci Rep. 6: 33346. PubMed
  88. Pawlicki JM, et al. 2021. Cancer Res. 81:3241. PubMed
RRID
AB_940360 (BioLegend Cat. No. 329707)
AB_940360 (BioLegend Cat. No. 329708)

Antigen Details

Distribution

T cells, B cells, NK cells, monocytes/macrophages, granulocytes and dendritic cells

Function
CD274 is involved in the costimulatory signal, essential for T lymphocyte proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-CD1-independent manner. Its interaction with PD-1-CD1 inhibits T-cell proliferation and cytokine production.
Ligand/Receptor
PD-1 (PDCD1)
Cell Type
B cells, Dendritic cells, Fibroblasts, Granulocytes, Macrophages, Monocytes, NK cells, T cells
Biology Area
Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family
Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.

Gene ID
29126 View all products for this Gene ID
UniProt
View information about CD274 on UniProt.org

Other Formats

View All CD274 Reagents Request Custom Conjugation
Description Clone Applications
Purified anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC,IHC-P,Block
Biotin anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
PE anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
APC anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Brilliant Violet 421™ anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Ultra-LEAF™ Purified anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC,IHC,Block
PE/Cyanine7 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Purified anti-human CD274 (B7-H1, PD-L1) (Maxpar® Ready) 29E.2A3 FC,CyTOF®
Brilliant Violet 711™ anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Brilliant Violet 605™ anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
GoInVivo™ Purified anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC,IHC,Block
PE/Dazzle™ 594 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Brilliant Violet 785™ anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Brilliant Violet 510™ anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
PerCP/Cyanine5.5 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Brilliant Violet 650™ anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Alexa Fluor® 594 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 IHC-P
TotalSeq™-A0007 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 PG
TotalSeq™-B0007 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 PG
TotalSeq™-C0007 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 PG
TotalSeq™-D0007 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 PG
PE/Fire™ 810 anti-human CD274 (B7-H1, PD-L1) Antibody 29E.2A3 FC
PE/Cyanine5 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Spark YG™ 570 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 IHC-P,FC
Go To Top Version: 7    Revision Date: 11/30/2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account